Preface

Chapter 1- Colorectal Cancer Subtypes- the current portrait. 1

Peter Jordan

Chapter 2- Targeting colon cancers with mutated BRAF and microsatellite instability. 17

Paulo Matos and Peter Jordan

Chapter 3 - Targeting KRAS mutant CMS3 subtype by metabolic inhibitors. 50

Oscar Aguilera and Roberto Serna-Blasco

Chapter 4- Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. 77

Chapter 5- Targeting PTEN in colorectal cancers. 117

Larissa Kotelevets, Mark G.H. Scott and Eric Chastre

Chapter 6- Wnt signalling-targeted therapy in the CMS2 tumour subtype: a new paradigm in CRC treatment? 162

Cristina Albuquerque and Lucília Pebre Pereira

Chapter 7- Impact of the microenvironment on tumour budding in colorectal cancer. 216

Chapter 8- Anti-EGFR Therapy to treat metastatic colorectal cancer: not for all 241

Marta Martins, André Mansinho, Raquel Duarte, Soraia Lobo Martins and Luís Costa

Chapter 9- miRNAs as modulators of EGFR therapy in colorectal cancer. 282

Diane M. Pereira and Cecília M. P. Rodrigues

Index

Peter Jordan is the President of the National Institute of Health Dr. Ricardo Jorge Scientific Committee. His research group is dedicated to the study of cancer's molecular and cellular biology.